[{"to": "74", "prefix": "\n\nCLINICAL PHARMACOLOGY\nPharmacokinetics Pharmacokinetics   ", "from": "61", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " is rapidly absorbed from the gastrointestinal tract after o"}, {"to": "207", "prefix": "ral administration. The absolute bioavailability of 250 mg ", "from": "194", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " tablets was approximately 50%. For a single 500 mg dose of "}, {"to": "281", "prefix": "tablets was approximately 50%. For a single 500 mg dose of ", "from": "268", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", food slightly delays the onset of clarithromycin absorptio"}, {"to": "331", "prefix": " dose of clarithromycin, food slightly delays the onset of ", "from": "318", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " absorption, increasing the peak time from approximately 2 t"}, {"to": "442", "prefix": "from approximately 2 to 2.5 hours. Food also increases the ", "from": "429", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " peak plasma concentration by about 24%, but does not affect"}, {"to": "531", "prefix": "centration by about 24%, but does not affect the extent of ", "from": "518", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " bioavailability. Food does not affect the onset of formatio"}, {"to": "655", "prefix": " formation of the antimicrobially active metabolite, 14-OH ", "from": "642", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " or its peak plasma concentration but does slightly decrease"}, {"to": "862", "prefix": ". Therefore, ", "from": "849", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " tablets may be given without regard to food.In nonfasting h"}, {"to": "1084", "prefix": "n 2 to 3 hours after oral dosing. Steady-state peak plasma ", "from": "1071", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " concentrations were attained within 3 days and were approxi"}, {"to": "1326", "prefix": "nistered every 8 to 12 hours. The elimination half-life of ", "from": "1313", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " was about 3 to 4 hours with 250 mg administered every 12 ho"}, {"to": "1500", "prefix": "0 mg administered every 8 to 12 hours. The nonlinearity of ", "from": "1487", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " pharmacokinetics is slight at the recommended doses of 250 "}, {"to": "1691", "prefix": " mg every 12 hours dosing, the principal metabolite, 14-OH ", "from": "1678", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", attains a peak steady-state concentration of about 0.6 mcg"}, {"to": "1906", "prefix": "hours dosing, the peak steady-state concentration of 14-OH ", "from": "1893", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " is slightly higher "}, {"to": "2233", "prefix": " approximately 20% of the dose is excreted in the urine as ", "from": "2220", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", while after a 500 mg tablet every 12 hours, the urinary ex"}, {"to": "2318", "prefix": "r a 500 mg tablet every 12 hours, the urinary excretion of ", "from": "2305", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " is somewhat greater, approximately 30% . In comparison, aft"}, {"to": "2501", "prefix": " every 12 hours, approximately 40% is excreted in urine as ", "from": "2488", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ". The renal clearance of clarithromycin is, however, relativ"}, {"to": "2540", "prefix": "xcreted in urine as clarithromycin. The renal clearance of ", "from": "2527", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " is, however, relatively independent of the dose size and ap"}, {"to": "2709", "prefix": "tration rate. The major metabolite found in urine is 14-OH ", "from": "2696", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", which accounts for an additional 10% to 15% of the dose wi"}, {"to": "2880", "prefix": "administered every 12 hours.Steady-state concentrations of ", "from": "2867", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and 14-OH clarithromycin observed following administration "}, {"to": "2905", "prefix": "rs.Steady-state concentrations of clarithromycin and 14-OH ", "from": "2892", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " observed following administration of 500 mg doses of clarit"}, {"to": "2973", "prefix": "mycin observed following administration of 500 mg doses of ", "from": "2960", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " every 12 hours to adult patients with HIV infection were si"}, {"to": "3158", "prefix": "ult HIV-infected patients taking 500 - or 1000-mg doses of ", "from": "3145", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " every 12 hours, steady-state clarithromycin Cmax values ran"}, {"to": "3202", "prefix": "00-mg doses of clarithromycin every 12 hours, steady-state ", "from": "3189", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " Cmax values ranged from 2 to 4 mcg"}, {"to": "3391", "prefix": "mL respectively.The steady-state concentrations of ", "from": "3378", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " in subjects with impaired hepatic function did not differ f"}, {"to": "3514", "prefix": "t differ from those in normal subjects; however, the 14-OH ", "from": "3501", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " concentrations were lower in the hepatically impaired subje"}, {"to": "3626", "prefix": "ically impaired subjects. The decreased formation of 14-OH ", "from": "3613", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " was at least partially offset by an increase in renal clear"}, {"to": "3708", "prefix": "east partially offset by an increase in renal clearance of ", "from": "3695", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " in the subjects with impaired hepatic function when compare"}, {"to": "3828", "prefix": " when compared to healthy subjects.The pharmacokinetics of ", "from": "3815", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " was also altered in subjects with impaired renal function. "}, {"to": "3966", "prefix": "PRECAUTIONS and ", "from": "3953", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " and the 14-OH clarithromycin metabolite distribute readily "}, {"to": "3995", "prefix": "PRECAUTIONS and Clarithromycin and the 14-OH ", "from": "3982", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " metabolite distribute readily into body tissues and fluids."}, {"to": "4375", "prefix": "\n\n\n\n\n", "from": "4362", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " 500 mg every 8 hours was given in combination with omeprazo"}, {"to": "4509", "prefix": "e 40 mg daily to healthy adult males. The plasma levels of ", "from": "4496", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and 14-hydroxy-clarithromycin were increased by the concomi"}, {"to": "4539", "prefix": " males. The plasma levels of clarithromycin and 14-hydroxy-", "from": "4526", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " were increased by the concomitant administration of omepraz"}, {"to": "4622", "prefix": "eased by the concomitant administration of omeprazole. For ", "from": "4609", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", the mean Cmax was 10% greater, the mean Cmin was 27% great"}, {"to": "4741", "prefix": " was 27% greater, and the mean AUC0-8 was 15% greater when ", "from": "4728", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " was administered with omeprazole than when clarithromycin w"}, {"to": "4799", "prefix": " clarithromycin was administered with omeprazole than when ", "from": "4786", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " was administered alone. Similar results were seen for 14-hy"}, {"to": "4879", "prefix": "ministered alone. Similar results were seen for 14-hydroxy-", "from": "4866", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", the mean Cmax was 45% greater, the mean Cmin was 57% great"}, {"to": "4994", "prefix": "Cmin was 57% greater, and the mean AUC0-8 was 45% greater. ", "from": "4981", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " concentrations in the gastric tissue and mucus were also in"}, {"to": "5221", "prefix": "nformation about other drugs indicated in combination with ", "from": "5208", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", refer to the CLINICAL PHARMACOLOGY section of their packag"}, {"to": "5374", "prefix": "HARMACOLOGY section of their package inserts.Microbiology: ", "from": "5361", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " exerts its antibacterial action by binding to the 50S ribos"}, {"to": "5550", "prefix": "resulting in inhibition of protein synthesis.Microbiology: ", "from": "5537", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " exerts its antibacterial action by binding to the 50S ribos"}, {"to": "5712", "prefix": "icroorganisms resulting in inhibition of protein synthesis.", "from": "5699", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " is active in vitro against a variety of aerobic and anaerob"}, {"to": "6040", "prefix": "ive microorganisms as well as most Additionally, the 14-OH ", "from": "6027", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " metabolite also has clinically significant antimicrobial ac"}, {"to": "6132", "prefix": "s clinically significant antimicrobial activity. The 14-OH ", "from": "6119", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " is twice as active against Haemophilus influenzae microorga"}, {"to": "6346", "prefix": "ates the 14-OH metabolite is 4 to 7 times less active than ", "from": "6333", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ". The clinical significance of this activity against Mycobac"}, {"to": "6527", "prefix": "uenzae microorganisms as the parent compound. However, for ", "from": "6514", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " has been shown to be active against most strains of the fol"}, {"to": "7321", "prefix": "moniae, Beta-lactamase production should have no effect on ", "from": "7308", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " activity.NOTE: Most strains of methicillin-resistant and ox"}, {"to": "7444", "prefix": "ant and oxacillin-resistant staphylococci are resistant to ", "from": "7431", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ". NOTE: Most strains of methicillin-resistant and oxacillin-"}, {"to": "7559", "prefix": "ant and oxacillin-resistant staphylococci are resistant to ", "from": "7546", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ". Omeprazole"}, {"to": "7586", "prefix": "", "from": "7573", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " dual therapy; ranitidine bismuth citrate"}, {"to": "7642", "prefix": "", "from": "7629", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " dual therapy; omeprazole"}, {"to": "7682", "prefix": "", "from": "7669", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "7742", "prefix": "", "from": "7729", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "8198", "prefix": "", "from": "8185", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " dual therapy studies "}, {"to": "8289", "prefix": "", "from": "8276", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "8360", "prefix": ". ", "from": "8347", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " pretreatment resistance was 12.6% "}, {"to": "8452", "prefix": "", "from": "8439", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " b.i.d. versus t.i.d. clinical study "}, {"to": "8515", "prefix": ". ", "from": "8502", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " pretreatment resistance rates were 9.5% "}, {"to": "8645", "prefix": "", "from": "8632", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "8879", "prefix": "", "from": "8866", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "9090", "prefix": " of the patients, all of whom were in the ", "from": "9077", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "9273", "prefix": "", "from": "9260", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "9641", "prefix": "mL by E-test.", "from": "9628", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " Susceptibility Test Results and Clinical"}, {"to": "9868", "prefix": "", "from": "9855", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", ranitidine bismuth citrate"}, {"to": "9911", "prefix": "", "from": "9898", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", omeprazole"}, {"to": "9938", "prefix": "", "from": "9925", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "9982", "prefix": "", "from": "9969", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "10035", "prefix": "amoxicillin therapy would likely have ", "from": "10022", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " resistant H. pylori isolates. Therefore, for patients who f"}, {"to": "10122", "prefix": "pylori isolates. Therefore, for patients who fail therapy, ", "from": "10109", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " susceptibility testing should be done, if possible. Patient"}, {"to": "10203", "prefix": "ibility testing should be done, if possible. Patients with ", "from": "10190", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " resistant H. pylori should not be treated with any of the f"}, {"to": "10298", "prefix": "", "from": "10285", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " dual therapy; ranitidine bismuth citrate"}, {"to": "10354", "prefix": "", "from": "10341", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " dual therapy; omeprazole"}, {"to": "10394", "prefix": "", "from": "10381", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "10450", "prefix": "", "from": "10437", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "10525", "prefix": "moxicillin triple therapy; or other regimens which include ", "from": "10512", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " as the sole antimicrobial agent. H. pylori following omepra"}, {"to": "10604", "prefix": "", "from": "10591", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", ranitidine bismuth citrate"}, {"to": "10647", "prefix": "", "from": "10634", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ", omeprazole"}, {"to": "10674", "prefix": "", "from": "10661", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "10718", "prefix": "", "from": "10705", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "10771", "prefix": "amoxicillin therapy would likely have ", "from": "10758", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " resistant Amoxicillin Susceptibility Test Results and Clini"}, {"to": "10969", "prefix": "", "from": "10956", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "11467", "prefix": "le therapy also had post-treatment H. pylori isolates with ", "from": "11454", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " resistant MICs.H. pylori and 15.1% "}, {"to": "11688", "prefix": "", "from": "11675", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "12280", "prefix": "tment MICs that failed the triple-therapy regimen also had ", "from": "12267", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " resistant H. pylori isolates. H. pylori. Of those with pret"}, {"to": "12506", "prefix": "are available, but their clinical significance is unknown. ", "from": "12493", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " exhibits in vitro activity against most strains of the foll"}, {"to": "12643", "prefix": "g microorganisms; however, the safety and effectiveness of ", "from": "12630", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " in treating clinical infections due to these microorganisms"}, {"to": "14097", "prefix": "inoculum concentrations and standardized concentrations of ", "from": "14084", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " powder. The MIC values should be interpreted according to t"}, {"to": "14302", "prefix": "inoculum concentrations and standardized concentrations of ", "from": "14289", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " powder. The MIC values should be interpreted according to t"}, {"to": "14652", "prefix": "Streptococcus pneumoniae, susceptibility and resistance to ", "from": "14639", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " can be predicted using erythromycin.Note: When testing A re"}, {"to": "15791", "prefix": "e technical aspects of the laboratory procedures. Standard ", "from": "15778", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " powder should provide the following MIC values:\n\n\n\n\nDiffusi"}, {"to": "16210", "prefix": "s. This procedure uses paper disks impregnated with 15 mcg ", "from": "16197", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " to test the susceptibility of microorganisms to clarithromy"}, {"to": "16273", "prefix": "ithromycin to test the susceptibility of microorganisms to ", "from": "16260", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ".2  requires the use of standardized inoculum concentrations"}, {"to": "16405", "prefix": "s. This procedure uses paper disks impregnated with 15 mcg ", "from": "16392", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " to test the susceptibility of microorganisms to clarithromy"}, {"to": "16468", "prefix": "ithromycin to test the susceptibility of microorganisms to ", "from": "16455", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ".Reports from the laboratory providing results of the standa"}, {"to": "16591", "prefix": "the standard single-disk susceptibility test with a 15 mcg ", "from": "16578", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " disk should be interpreted according to the following crite"}, {"to": "16920", "prefix": "Streptococcus pneumoniae, susceptibility and resistance to ", "from": "16907", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " can be predicted using erythromycin. Streptococcus spp.Inte"}, {"to": "17165", "prefix": "of the diameter obtained in the disk test with the MIC for ", "from": "17152", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ".As with standardized dilution techniques, diffusion methods"}, {"to": "17410", "prefix": "ratory procedures. For the diffusion technique, the 15 mcg ", "from": "17397", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " disk should provide the following zone diameters in this la"}, {"to": "17547", "prefix": "tory test quality control strain:\n\n\n\n\nIn Vitro Activity of ", "from": "17534", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " against Myobacteria  In Vitro Activity of Clarithromycin aga"}, {"to": "17603", "prefix": "of Clarithromycin against Myobacteria  In Vitro Activity of ", "from": "17590", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " against Myobacteria    Clarithromycin has demonstrated in vit"}, {"to": "17639", "prefix": "a  In Vitro Activity of Clarithromycin against Myobacteria    ", "from": "17626", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " has demonstrated in vitro activity against Mycobacterium av"}, {"to": "18280", "prefix": ", have been used to determine ", "from": "18267", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " MIC values for mycobacterial species. In general, MIC value"}, {"to": "18865", "prefix": ", have been used to determine ", "from": "18852", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " MIC values for mycobacterial species. In general, MIC value"}, {"to": "19287", "prefix": "in these assays has been shown to further alter MIC values.", "from": "19274", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " activity against 80 MAC isolates from AIDS patients and 211"}, {"to": "19653", "prefix": "mL. ", "from": "19640", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " was also shown to be active against phagocytized M. avium c"}, {"to": "19943", "prefix": "ell cultures as well as in the beige mouse infection model.", "from": "19930", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " activity was evaluated against Mycobacterium tuberculosis m"}, {"to": "20161", "prefix": "mL. ", "from": "20148", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " inhibited all isolates at "}, {"to": "20386", "prefix": "mL. ", "from": "20373", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " inhibited all isolates at "}, {"to": "20655", "prefix": " gram-negative bacteria should not be used for determining ", "from": "20642", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " MIC values against mycobacteria. In vitro susceptibility te"}, {"to": "20942", "prefix": " organisms have not been standardized or validated. ", "from": "20929", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " MIC values will vary depending on the susceptibility testin"}, {"to": "21232", "prefix": "avium or M. intracellulare are susceptible or resistant to ", "from": "21219", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " have not been established.Susceptibility  Testing for Mycoba"}, {"to": "21489", "prefix": " gram-negative bacteria should not be used for determining ", "from": "21476", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " MIC values against mycobacteria. Susceptibility Test for He"}, {"to": "22244", "prefix": "bial agent required to inhibit growth of the organism. The ", "from": "22231", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and amoxicillin MIC values should be interpreted according "}, {"to": "22620", "prefix": "e technical aspects of the laboratory procedures. Standard ", "from": "22607", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and amoxicillin powders should provide the following MIC va"}, {"to": "4437", "prefix": "romycin 500 mg every 8 hours was given in combination with ", "from": "4428", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": " 40 mg daily to healthy adult males. The plasma levels of cl"}, {"to": "4602", "prefix": "omycin were increased by the concomitant administration of ", "from": "4593", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ". For clarithromycin, the mean Cmax was 10% greater, the mea"}, {"to": "4774", "prefix": " was 15% greater when clarithromycin was administered with ", "from": "4765", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": " than when clarithromycin was administered alone. Similar re"}, {"to": "5105", "prefix": "mucus were also increased by concomitant administration of ", "from": "5096", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ".max was 10% greater, the mean C\n\n\n\n\n  For information about "}, {"to": "7571", "prefix": "n-resistant staphylococci are resistant to clarithromycin. ", "from": "7562", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Omeprazole", "suffix": ""}, {"to": "7667", "prefix": "clarithromycin dual therapy; ", "from": "7658", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "8183", "prefix": " in the ", "from": "8174", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "8274", "prefix": " in the ", "from": "8265", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "8864", "prefix": " of the patients in the ", "from": "8855", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "9853", "prefix": "comesaa\n\n\n\n\nPatients not eradicated of H. pylori following ", "from": "9844", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "9923", "prefix": "clarithromycin, ", "from": "9914", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "10283", "prefix": "H. pylori should not be treated with any of the following: ", "from": "10274", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "10379", "prefix": "clarithromycin dual therapy; ", "from": "10370", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "10589", "prefix": "mycin as the sole antimicrobial agent. H. pylori following ", "from": "10580", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "10659", "prefix": "clarithromycin, ", "from": "10650", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "10954", "prefix": "Bacteriological Outcomes  In the ", "from": "10945", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": ""}, {"to": "7364", "prefix": "no effect on clarithromycin activity.NOTE: Most strains of ", "from": "7354", "name": "Methicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008712", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "methicillin", "suffix": "-resistant and oxacillin-resistant staphylococci are resista"}, {"to": "7479", "prefix": "cci are resistant to clarithromycin. NOTE: Most strains of ", "from": "7469", "name": "Methicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008712", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "methicillin", "suffix": "-resistant and oxacillin-resistant staphylococci are resista"}, {"to": "7388", "prefix": "n activity.NOTE: Most strains of methicillin-resistant and ", "from": "7380", "name": "Oxacillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D010068", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "oxacillin", "suffix": "-resistant staphylococci are resistant to clarithromycin. NO"}, {"to": "7503", "prefix": "thromycin. NOTE: Most strains of methicillin-resistant and ", "from": "7495", "name": "Oxacillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D010068", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "oxacillin", "suffix": "-resistant staphylococci are resistant to clarithromycin. Om"}, {"to": "7627", "prefix": "clarithromycin dual therapy; ", "from": "7602", "name": "ranitidine bismuth citrate", "fullId": "http://purl.bioontology.org/ontology/MESH/C073340", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ranitidine bismuth citrate", "suffix": ""}, {"to": "8437", "prefix": " in the ", "from": "8412", "name": "ranitidine bismuth citrate", "fullId": "http://purl.bioontology.org/ontology/MESH/C073340", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ranitidine bismuth citrate", "suffix": ""}, {"to": "9896", "prefix": "clarithromycin, ", "from": "9871", "name": "ranitidine bismuth citrate", "fullId": "http://purl.bioontology.org/ontology/MESH/C073340", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ranitidine bismuth citrate", "suffix": ""}, {"to": "10339", "prefix": "clarithromycin dual therapy; ", "from": "10314", "name": "ranitidine bismuth citrate", "fullId": "http://purl.bioontology.org/ontology/MESH/C073340", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ranitidine bismuth citrate", "suffix": ""}, {"to": "10632", "prefix": "clarithromycin, ", "from": "10607", "name": "ranitidine bismuth citrate", "fullId": "http://purl.bioontology.org/ontology/MESH/C073340", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ranitidine bismuth citrate", "suffix": ""}, {"to": "7694", "prefix": "", "from": "7684", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple therapy; and lansoprazole"}, {"to": "7754", "prefix": "", "from": "7744", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple therapy have been shown to be active against most st"}, {"to": "8301", "prefix": "", "from": "8291", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple-therapy studies "}, {"to": "8657", "prefix": "", "from": "8647", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple therapy clinical trials "}, {"to": "8751", "prefix": ".", "from": "8741", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Amoxicillin", "suffix": " pretreatment susceptible isolates "}, {"to": "8891", "prefix": "", "from": "8881", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " clinical studies "}, {"to": "8941", "prefix": ". ", "from": "8931", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Amoxicillin", "suffix": " pretreatment minimum inhibitory concentrations "}, {"to": "9102", "prefix": "", "from": "9092", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " study arm. Amoxicillin pretreatment susceptible isolates "}, {"to": "9125", "prefix": "amoxicillin study arm. ", "from": "9115", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Amoxicillin", "suffix": " pretreatment susceptible isolates "}, {"to": "9285", "prefix": "", "from": "9275", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple-therapy clinical trials by E-test and agar dilution,"}, {"to": "9468", "prefix": " by agar dilution had ", "from": "9458", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " pretreatment MICs of "}, {"to": "9561", "prefix": "mL. Two patients had an unconfirmed pretreatment ", "from": "9551", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " minimum inhibitory concentration "}, {"to": "9950", "prefix": "", "from": "9940", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": ", or lansoprazole"}, {"to": "9994", "prefix": "", "from": "9984", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " therapy would likely have clarithromycin resistant H. pylor"}, {"to": "10406", "prefix": "", "from": "10396", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple therapy; lansoprazole"}, {"to": "10462", "prefix": "", "from": "10452", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple therapy; or other regimens which include clarithromy"}, {"to": "10686", "prefix": "", "from": "10676", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": ", or lansoprazole"}, {"to": "10730", "prefix": "", "from": "10720", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " therapy would likely have clarithromycin resistant Amoxicil"}, {"to": "10793", "prefix": "icillin therapy would likely have clarithromycin resistant ", "from": "10783", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Amoxicillin", "suffix": " Susceptibility Test Results and Clinical"}, {"to": "10981", "prefix": "", "from": "10971", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple-therapy clinical trials, 84.9% "}, {"to": "11078", "prefix": " of the patients who had pretreatment ", "from": "11068", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " susceptible MICs "}, {"to": "11337", "prefix": "results, and 17 had post-treatment H. pylori isolates with ", "from": "11327", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " susceptible MICs. Eleven of the patients who failed triple "}, {"to": "11700", "prefix": "", "from": "11690", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " triple-therapy clinical trials, 82.6% "}, {"to": "11798", "prefix": " of the patients that had pretreatment ", "from": "11788", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " susceptible MICs "}, {"to": "11900", "prefix": " were eradicated of H. pylori. Of those with pretreatment ", "from": "11890", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " MICs of "}, {"to": "12197", "prefix": " patients who failed therapy. Nine of the 11 patients with ", "from": "12187", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " post-treatment MICs that failed the triple-therapy regimen "}, {"to": "12360", "prefix": " H. pylori isolates. H. pylori. Of those with pretreatment ", "from": "12350", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " MICs of "}, {"to": "22260", "prefix": " to inhibit growth of the organism. The clarithromycin and ", "from": "22250", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " MIC values should be interpreted according to the following"}, {"to": "22636", "prefix": " of the laboratory procedures. Standard clarithromycin and ", "from": "22626", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "amoxicillin", "suffix": " powders should provide the following MIC values:\n\n\n"}, {"to": "14688", "prefix": "ty and resistance to clarithromycin can be predicted using ", "from": "14677", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "erythromycin", "suffix": ".Note: When testing A report of "}, {"to": "16956", "prefix": "ty and resistance to clarithromycin can be predicted using ", "from": "16945", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "erythromycin", "suffix": ". Streptococcus spp.Interpretation should be as stated above"}, {"to": "187", "prefix": "    Drug interaction studies have been completed with both ", "from": "180", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " and saquinavir soft gel capsules. Observations from drug in"}, {"to": "202", "prefix": "raction studies have been completed with both INVIRASE and ", "from": "193", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " soft gel capsules. Observations from drug interaction studi"}, {"to": "280", "prefix": " capsules. Observations from drug interaction studies with ", "from": "271", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " soft gel capsules may not be predictive for INVIRASE"}, {"to": "333", "prefix": "ith saquinavir soft gel capsules may not be predictive for ", "from": "326", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "394", "prefix": "ritonavir. Because ritonavir is coadministered with ", "from": "387", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ", prescribers should also refer to the prescribing informati"}, {"to": "677", "prefix": "     \n                        \n                            ", "from": "670", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "861", "prefix": "\n                            Coadministration of ", "from": "854", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "960", "prefix": "uce CYP3A may result in decreased plasma concentrations of ", "from": "951", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " and reduced efficacy. "}, {"to": "1089", "prefix": "in drugs or drug classes should not be coadministered with ", "from": "1082", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "1390", "prefix": "Potential for ", "from": "1383", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " to Affect Other Drugs\n                     \n               "}, {"to": "1483", "prefix": "                  \n                        The combination ", "from": "1476", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "2311", "prefix": "Potential for Other Drugs to Affect ", "from": "2304", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": "\n                     \n                        The metabolis"}, {"to": "2386", "prefix": "                \n                        The metabolism of ", "from": "2377", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " is mediated primarily by CYP3A. Additionally, saquinavir is"}, {"to": "2443", "prefix": "f saquinavir is mediated primarily by CYP3A. Additionally, ", "from": "2434", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " is a substrate for P-glycoprotein "}, {"to": "2578", "prefix": "or P-gp may modify the pharmacokinetics of ", "from": "2569", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": ". Coadministration with drugs that are potent inducers of CY"}, {"to": "2749", "prefix": " may result in decreased plasma concentrations of ", "from": "2740", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " and reduced therapeutic effect.\n                     \n     "}, {"to": "3192", "prefix": "ons of QT and PR intervals in healthy volunteers receiving ", "from": "3185", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "3673", "prefix": " Therefore, concurrent administration of these agents with ", "from": "3666", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "343", "prefix": "", "from": "335", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": ". Because ritonavir is coadministered with INVIRASE, prescri"}, {"to": "362", "prefix": "ritonavir. Because ", "from": "354", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " is coadministered with INVIRASE, prescribers should also re"}, {"to": "470", "prefix": "ibers should also refer to the prescribing information for ", "from": "462", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " regarding drug interactions associated with this agent.\n   "}, {"to": "687", "prefix": "", "from": "679", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " is a potent inhibitor of CYP3A, significantly increasing th"}, {"to": "871", "prefix": "", "from": "863", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " with drugs that induce CYP3A may result in decreased plasma"}, {"to": "1099", "prefix": "", "from": "1091", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " based on drug interaction studies or predicted drug interac"}, {"to": "1493", "prefix": "", "from": "1485", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " is a potent inhibitor of CYP3A and may significantly increa"}, {"to": "3202", "prefix": "", "from": "3194", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": ", additive effects on QT and"}, {"to": "3683", "prefix": "", "from": "3675", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " is contraindicated [see Contraindications "}, {"to": "2662", "prefix": "e.g., ", "from": "2650", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "phenobarbital", "suffix": ", phenytoin, carbamazepine"}, {"to": "2673", "prefix": "e.g., phenobarbital, ", "from": "2665", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "phenytoin", "suffix": ", carbamazepine"}, {"to": "2688", "prefix": "e.g., phenobarbital, phenytoin, ", "from": "2676", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "carbamazepine", "suffix": ""}, {"to": "35", "prefix": "\n\n\nDrug interactions\n", "from": "22", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " use in patients who are receiving theophylline may be assoc"}, {"to": "412", "prefix": "In two studies in which theophylline was administered with ", "from": "399", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " "}, {"to": "548", "prefix": "kg together with 250 or 500 mg ql2h ", "from": "535", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ""}, {"to": "752", "prefix": "ut 20%.max, CConcomitant administration of single doses of ", "from": "739", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and carbamazepine has been shown to result in increased pla"}, {"to": "926", "prefix": "d level monitoring of carbamazepine may be considered.When ", "from": "913", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and terfenadine were coadministered, plasma concentrations "}, {"to": "1170", "prefix": "erfenadine was administered alone. The pharmacokinetics of ", "from": "1157", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and the 14-hydroxy-clarithromycin were not significantly af"}, {"to": "1204", "prefix": " The pharmacokinetics of clarithromycin and the 14-hydroxy-", "from": "1191", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " were not significantly affected by coadministration of terf"}, {"to": "1291", "prefix": "ificantly affected by coadministration of terfenadine once ", "from": "1278", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " reached steadystate conditions. Concomitant administration "}, {"to": "1368", "prefix": "ched steadystate conditions. Concomitant administration of ", "from": "1355", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with terfenadine is contraindicated. "}, {"to": "1463", "prefix": "", "from": "1450", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " 500 mg every 8 hours was given in combination with omeprazo"}, {"to": "1756", "prefix": ", by the concomitant administration of ", "from": "1743", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ". The mean 24-hour gastric pH value was 5.2 when omeprazole "}, {"to": "1886", "prefix": "le was administered alone and 5.7 when coadministered with ", "from": "1873", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ".0-24, and TCoadministration of clarithromycin with ranitidi"}, {"to": "1932", "prefix": "istered with clarithromycin.0-24, and TCoadministration of ", "from": "1919", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with ranitidine bismuth citrate resulted in increased plasm"}, {"to": "2242", "prefix": "inically insignificant.Simultaneous oral administration of ", "from": "2229", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " tablets and zidovudine to HIV infected adult patients resul"}, {"to": "2388", "prefix": "sed steady-state zidovudine concentrations. When 500 mg of ", "from": "2375", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " were administered twice daily, steady-state zidovudine AUC "}, {"to": "2612", "prefix": "ncrease of 14%. Based on limited data in 24 patients, when ", "from": "2599", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " tablets were administered two to four hours prior to oral z"}, {"to": "3115", "prefix": "Concomitant administration of fluconazole 200 mg daily and ", "from": "3102", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " 500 mg twice daily to 21 healthy volunteers led to increase"}, {"to": "3216", "prefix": "althy volunteers led to increases in the mean steady-state ", "from": "3203", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " Cmin and AUC of 33% and 18%, respectively. Steady-state con"}, {"to": "3311", "prefix": "nd 18%, respectively. Steady-state concentrations of 14-OH ", "from": "3298", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " were not significantly affected by concomitant administrati"}, {"to": "3482", "prefix": "nd 18%, respectively. Steady-state concentrations of 14-OH ", "from": "3469", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " were not significantly affected by concomitant administrati"}, {"to": "3604", "prefix": "dministration of fluconazole.Concomitant administration of ", "from": "3591", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and ritonavir "}, {"to": "3670", "prefix": " resulted in a 77% increase in ", "from": "3657", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " AUC and a 100% decrease in the AUC of 14-OH clarithromycin."}, {"to": "3729", "prefix": "clarithromycin AUC and a 100% decrease in the AUC of 14-OH ", "from": "3716", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ". Clarithromycin may be administered without dosage adjustme"}, {"to": "3745", "prefix": "UC and a 100% decrease in the AUC of 14-OH clarithromycin. ", "from": "3732", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " may be administered without dosage adjustment to patients w"}, {"to": "4015", "prefix": "min, the dose of ", "from": "4002", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " should be reduced by 50%. For patients with CLCR "}, {"to": "4104", "prefix": "min, the dose of ", "from": "4091", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " should be decreased by 75%.Spontaneous reports in the postm"}, {"to": "4237", "prefix": "arketing period suggest that concomitant administration of ", "from": "4224", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and oral anticoagulants may potentiate the effects of the o"}, {"to": "4408", "prefix": "should be carefully monitored while patients are receiving ", "from": "4395", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and oral anticoagulants simultaneously.Elevated digoxin ser"}, {"to": "4522", "prefix": "levated digoxin serum concentrations in patients receiving ", "from": "4509", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and digoxin concomitantly have also been reported in postma"}, {"to": "4833", "prefix": "refully monitored while patients are receiving digoxin and ", "from": "4820", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " simultaneously.Colchicine is a substrate for both CYP3A and"}, {"to": "4954", "prefix": ". ", "from": "4941", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Clarithromycin", "suffix": " and other macrolides are known to inhibit CYP3A and Pgp. Wh"}, {"to": "5031", "prefix": " other macrolides are known to inhibit CYP3A and Pgp. When ", "from": "5018", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and colchicine are administered together, inhibition of Pgp"}, {"to": "5122", "prefix": "or CYP3A by ", "from": "5109", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " may lead to increased exposure to colchicine. Patients shou"}, {"to": "5300", "prefix": "Erythromycin and ", "from": "5287", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " are substrates and inhibitors of the 3A isoform subfamily o"}, {"to": "5455", "prefix": ". Coadministration of erythromycin or ", "from": "5442", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and a drug primarily metabolized by CYP3A may be associated"}, {"to": "5846", "prefix": "ld be monitored closely in patients concurrently receiving ", "from": "5833", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " or erythromycin.The following are examples of some clinical"}, {"to": "6180", "prefix": "olite of terfenadine were observed in clinical trials with ", "from": "6167", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": ".The following CYP3A based drug interactions have been obser"}, {"to": "6297", "prefix": "or with ", "from": "6284", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " in postmarketing experience.Antiarrhythmics: There have bee"}, {"to": "6451", "prefix": "ts of torsades de pointes occurring with concurrent use of ", "from": "6438", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and quinidine or disopyramide. Electrocardiograms should be"}, {"to": "6584", "prefix": " monitored for QTc prolongation during coadministration of ", "from": "6571", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with these drugs. Serum concentrations of these medications"}, {"to": "6795", "prefix": "ts of torsades de pointes occurring with concurrent use of ", "from": "6782", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and quinidine or disopyramide. Electrocardiograms should be"}, {"to": "6928", "prefix": " monitored for QTc prolongation during coadministration of ", "from": "6915", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with these drugs. Serum concentrations of these medications"}, {"to": "7115", "prefix": ": Post-marketing reports indicate that coadministration of ", "from": "7102", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with ergotamine or dihydroergotamine has been associated wi"}, {"to": "7358", "prefix": " the central nervous system. Concomitant administration of ", "from": "7345", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with ergotamine or dihydroergotamine is contraindicated "}, {"to": "7540", "prefix": ": Post-marketing reports indicate that coadministration of ", "from": "7527", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with ergotamine or dihydroergotamine has been associated wi"}, {"to": "7783", "prefix": " the central nervous system. Concomitant administration of ", "from": "7770", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with ergotamine or dihydroergotamine is contraindicated "}, {"to": "8264", "prefix": " with the concomitant use of ", "from": "8251", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " and triazolam.Triazolobenziodidiazepines "}, {"to": "8385", "prefix": "as HMG-CoA Reductase Inhibitors: As with other macrolides, ", "from": "8372", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " has been reported to increase concentrations of HMG-CoA red"}, {"to": "8664", "prefix": "ly.HMG-CoA Reductase Inhibitors: As with other macrolides, ", "from": "8651", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " has been reported to increase concentrations of HMG-CoA red"}, {"to": "9031", "prefix": " of sildenafil. A similar interaction may occur with ", "from": "9018", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": "; reduction of sildenafil dosage should be considered. "}, {"to": "9272", "prefix": " of sildenafil. A similar interaction may occur with ", "from": "9259", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": "; reduction of sildenafil dosage should be considered. "}, {"to": "9469", "prefix": "or ", "from": "9456", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with cyclosporine, carbamazepine, tacrolimus, alfentanil, d"}, {"to": "9658", "prefix": "ilostazol, and bromocriptine.Concomitant administration of ", "from": "9645", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with cisapride, pimozide, astemizole, or terfenadine is con"}, {"to": "9860", "prefix": "there have been reports of interactions of erythromycin or ", "from": "9847", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "clarithromycin", "suffix": " with drugs not thought to be metabolized by CYP3A, includin"}, {"to": "82", "prefix": "eractions\nClarithromycin use in patients who are receiving ", "from": "71", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "theophylline", "suffix": " may be associated with an increase of serum theophylline co"}, {"to": "139", "prefix": "g theophylline may be associated with an increase of serum ", "from": "128", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "theophylline", "suffix": " concentrations. Monitoring of serum theophylline concentrat"}, {"to": "188", "prefix": " of serum theophylline concentrations. Monitoring of serum ", "from": "177", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "theophylline", "suffix": " concentrations should be considered for patients receiving "}, {"to": "274", "prefix": " should be considered for patients receiving high doses of ", "from": "263", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "theophylline", "suffix": " or with baseline concentrations in the upper therapeutic ra"}, {"to": "375", "prefix": "ns in the upper therapeutic range. In two studies in which ", "from": "364", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "theophylline", "suffix": " was administered with clarithromycin "}, {"to": "428", "prefix": "a ", "from": "417", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "theophylline", "suffix": " sustained-release formulation was dosed at either 6.5 mg"}, {"to": "665", "prefix": " of ", "from": "654", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "theophylline", "suffix": " increased about 20%.max, CConcomitant administration of sin"}, {"to": "770", "prefix": "itant administration of single doses of clarithromycin and ", "from": "758", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "carbamazepine", "suffix": " has been shown to result in increased plasma concentrations"}, {"to": "847", "prefix": "been shown to result in increased plasma concentrations of ", "from": "835", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "carbamazepine", "suffix": ". Blood level monitoring of carbamazepine may be considered."}, {"to": "888", "prefix": "concentrations of carbamazepine. Blood level monitoring of ", "from": "876", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "carbamazepine", "suffix": " may be considered.When clarithromycin and terfenadine were "}, {"to": "6081", "prefix": "oform are also possible. Increased serum concentrations of ", "from": "6069", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "carbamazepine", "suffix": " and the active acid metabolite of terfenadine were observed"}, {"to": "9502", "prefix": "or clarithromycin with cyclosporine, ", "from": "9490", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "carbamazepine", "suffix": ", tacrolimus, alfentanil, disopyramide, rifabutin, quinidine"}, {"to": "942", "prefix": "of carbamazepine may be considered.When clarithromycin and ", "from": "932", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "terfenadine", "suffix": " were coadministered, plasma concentrations of the active ac"}, {"to": "1030", "prefix": "ed, plasma concentrations of the active acid metabolite of ", "from": "1020", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "terfenadine", "suffix": " were threefold higher, on average, than the values observed"}, {"to": "1107", "prefix": "hreefold higher, on average, than the values observed when ", "from": "1097", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "terfenadine", "suffix": " was administered alone. The pharmacokinetics of clarithromy"}, {"to": "1271", "prefix": "cin were not significantly affected by coadministration of ", "from": "1261", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "terfenadine", "suffix": " once clarithromycin reached steadystate conditions. Concomi"}, {"to": "1385", "prefix": "ditions. Concomitant administration of clarithromycin with ", "from": "1375", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "terfenadine", "suffix": " is contraindicated. "}, {"to": "6127", "prefix": "rations of carbamazepine and the active acid metabolite of ", "from": "6117", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "terfenadine", "suffix": " were observed in clinical trials with clarithromycin.The fo"}, {"to": "9711", "prefix": "of clarithromycin with cisapride, pimozide, astemizole, or ", "from": "9701", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "terfenadine", "suffix": " is contraindicated "}, {"to": "1525", "prefix": "romycin 500 mg every 8 hours was given in combination with ", "from": "1516", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": " 40 mg daily to healthy adult subjects. The steady-state pla"}, {"to": "1617", "prefix": " adult subjects. The steady-state plasma concentrations of ", "from": "1608", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": " were increased "}, {"to": "1815", "prefix": "ithromycin. The mean 24-hour gastric pH value was 5.2 when ", "from": "1806", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "omeprazole", "suffix": " was administered alone and 5.7 when coadministered with cla"}, {"to": "1964", "prefix": "romycin.0-24, and TCoadministration of clarithromycin with ", "from": "1939", "name": "ranitidine bismuth citrate", "fullId": "http://purl.bioontology.org/ontology/MESH/C073340", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ranitidine bismuth citrate", "suffix": " resulted in increased plasma ranitidine concentrations "}, {"to": "2004", "prefix": "th ranitidine bismuth citrate resulted in increased plasma ", "from": "1995", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9143", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ranitidine", "suffix": " concentrations "}, {"to": "2265", "prefix": "ltaneous oral administration of clarithromycin tablets and ", "from": "2256", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "zidovudine", "suffix": " to HIV infected adult patients resulted in decreased steady"}, {"to": "2342", "prefix": "infected adult patients resulted in decreased steady-state ", "from": "2333", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "zidovudine", "suffix": " concentrations. When 500 mg of clarithromycin were administ"}, {"to": "2443", "prefix": "clarithromycin were administered twice daily, steady-state ", "from": "2434", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "zidovudine", "suffix": " AUC was reduced by a mean of 12% "}, {"to": "2681", "prefix": " tablets were administered two to four hours prior to oral ", "from": "2672", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "zidovudine", "suffix": ", the steady-state zidovudine Cmax was increased by approxim"}, {"to": "2710", "prefix": "o to four hours prior to oral zidovudine, the steady-state ", "from": "2701", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "zidovudine", "suffix": " Cmax was increased by approximately 2-fold, whereas the AUC"}, {"to": "2928", "prefix": ".Simultaneous administration of clarithromycin tablets and ", "from": "2919", "name": "Didanosine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3364", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "didanosine", "suffix": " to 12 HIV-infected adult patients resulted in no statistica"}, {"to": "3024", "prefix": "atients resulted in no statistically significant change in ", "from": "3015", "name": "Didanosine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3364", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "didanosine", "suffix": " pharmacokinetics.Concomitant administration of fluconazole "}, {"to": "3083", "prefix": " didanosine pharmacokinetics.Concomitant administration of ", "from": "3073", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "fluconazole", "suffix": " 200 mg daily and clarithromycin 500 mg twice daily to 21 he"}, {"to": "3388", "prefix": "ot significantly affected by concomitant administration of ", "from": "3378", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "fluconazole", "suffix": ".min and AUC of 33% and 18%, respectively. Steady-state conc"}, {"to": "3559", "prefix": "ot significantly affected by concomitant administration of ", "from": "3549", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "fluconazole", "suffix": ".Concomitant administration of clarithromycin and ritonavir "}, {"to": "3618", "prefix": "uconazole.Concomitant administration of clarithromycin and ", "from": "3610", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ritonavir", "suffix": " "}, {"to": "3847", "prefix": "e adjustment to patients with normal renal function taking ", "from": "3839", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ritonavir", "suffix": ". However, for patients with renal impairment, the following"}, {"to": "4328", "prefix": "nts may potentiate the effects of the oral anticoagulants. ", "from": "4318", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Prothrombin", "suffix": " times should be carefully monitored while patients are rece"}, {"to": "4464", "prefix": "ithromycin and oral anticoagulants simultaneously.Elevated ", "from": "4458", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "digoxin", "suffix": " serum concentrations in patients receiving clarithromycin a"}, {"to": "4534", "prefix": "um concentrations in patients receiving clarithromycin and ", "from": "4528", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "digoxin", "suffix": " concomitantly have also been reported in postmarketing surv"}, {"to": "4667", "prefix": "e. Some patients have shown clinical signs consistent with ", "from": "4661", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "digoxin", "suffix": " toxicity, including potentially fatal arrhythmias. Serum di"}, {"to": "4732", "prefix": "n toxicity, including potentially fatal arrhythmias. Serum ", "from": "4726", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "digoxin", "suffix": " concentrations should be carefully monitored while patients"}, {"to": "4814", "prefix": "should be carefully monitored while patients are receiving ", "from": "4808", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "digoxin", "suffix": " and clarithromycin simultaneously.Colchicine is a substrate"}, {"to": "4859", "prefix": "ts are receiving digoxin and clarithromycin simultaneously.", "from": "4850", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Colchicine", "suffix": " is a substrate for both CYP3A and the efflux transporter, P"}, {"to": "5046", "prefix": "re known to inhibit CYP3A and Pgp. When clarithromycin and ", "from": "5037", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "colchicine", "suffix": " are administered together, inhibition of Pgp and"}, {"to": "5167", "prefix": " CYP3A by clarithromycin may lead to increased exposure to ", "from": "5158", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "colchicine", "suffix": ". Patients should be monitored for clinical symptoms of colc"}, {"to": "5233", "prefix": "ine. Patients should be monitored for clinical symptoms of ", "from": "5224", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "colchicine", "suffix": " toxicity. "}, {"to": "5281", "prefix": "", "from": "5270", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Erythromycin", "suffix": " and clarithromycin are substrates and inhibitors of the 3A "}, {"to": "5437", "prefix": ". Coadministration of ", "from": "5426", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "erythromycin", "suffix": " or clarithromycin and a drug primarily metabolized by CYP3A"}, {"to": "5862", "prefix": "osely in patients concurrently receiving clarithromycin or ", "from": "5851", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "erythromycin", "suffix": ".The following are examples of some clinically significant C"}, {"to": "6261", "prefix": "wing CYP3A based drug interactions have been observed with ", "from": "6250", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "erythromycin", "suffix": " products and"}, {"to": "7967", "prefix": ":", "from": "7956", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Erythromycin", "suffix": " has been reported to decrease the clearance of triazolam an"}, {"to": "8906", "prefix": " :", "from": "8895", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Erythromycin", "suffix": " has been reported to increase the systemic exposure "}, {"to": "9147", "prefix": " :", "from": "9136", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Erythromycin", "suffix": " has been reported to increase the systemic exposure "}, {"to": "9447", "prefix": "aneous or published reports of CYP3A based interactions of ", "from": "9436", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "erythromycin", "suffix": " and"}, {"to": "9842", "prefix": "In addition, there have been reports of interactions of ", "from": "9831", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "erythromycin", "suffix": " or clarithromycin with drugs not thought to be metabolized "}, {"to": "6465", "prefix": "ointes occurring with concurrent use of clarithromycin and ", "from": "6457", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "quinidine", "suffix": " or disopyramide. Electrocardiograms should be monitored for"}, {"to": "6809", "prefix": "ointes occurring with concurrent use of clarithromycin and ", "from": "6801", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "quinidine", "suffix": " or disopyramide. Electrocardiograms should be monitored for"}, {"to": "9562", "prefix": "mazepine, tacrolimus, alfentanil, disopyramide, rifabutin, ", "from": "9554", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "quinidine", "suffix": ", methylprednisolone, cilostazol, and bromocriptine.Concomit"}, {"to": "6481", "prefix": "ing with concurrent use of clarithromycin and quinidine or ", "from": "6470", "name": "Disopyramide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3541", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "disopyramide", "suffix": ". Electrocardiograms should be monitored for QTc prolongatio"}, {"to": "6825", "prefix": "ing with concurrent use of clarithromycin and quinidine or ", "from": "6814", "name": "Disopyramide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3541", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "disopyramide", "suffix": ". Electrocardiograms should be monitored for QTc prolongatio"}, {"to": "9540", "prefix": " with cyclosporine, carbamazepine, tacrolimus, alfentanil, ", "from": "9529", "name": "Disopyramide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3541", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "disopyramide", "suffix": ", rifabutin, quinidine, methylprednisolone, cilostazol, and "}, {"to": "7024", "prefix": "ncentrations of these medications should also be monitored.", "from": "7015", "name": "Ergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4025", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Ergotamine", "suffix": ""}, {"to": "7131", "prefix": "orts indicate that coadministration of clarithromycin with ", "from": "7122", "name": "Ergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4025", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ergotamine", "suffix": " or dihydroergotamine has been associated with acute ergot t"}, {"to": "7374", "prefix": " system. Concomitant administration of clarithromycin with ", "from": "7365", "name": "Ergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4025", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ergotamine", "suffix": " or dihydroergotamine is contraindicated "}, {"to": "7449", "prefix": ".", "from": "7440", "name": "Ergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4025", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Ergotamine", "suffix": ""}, {"to": "7556", "prefix": "orts indicate that coadministration of clarithromycin with ", "from": "7547", "name": "Ergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4025", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ergotamine", "suffix": " or dihydroergotamine has been associated with acute ergot t"}, {"to": "7799", "prefix": " system. Concomitant administration of clarithromycin with ", "from": "7790", "name": "Ergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4025", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "ergotamine", "suffix": " or dihydroergotamine is contraindicated "}, {"to": "7042", "prefix": "", "from": "7026", "name": "Dihydroergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3418", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "dihydroergotamine", "suffix": ": Post-marketing reports indicate that coadministration of c"}, {"to": "7152", "prefix": "that coadministration of clarithromycin with ergotamine or ", "from": "7136", "name": "Dihydroergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3418", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "dihydroergotamine", "suffix": " has been associated with acute ergot toxicity characterized"}, {"to": "7395", "prefix": "mitant administration of clarithromycin with ergotamine or ", "from": "7379", "name": "Dihydroergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3418", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "dihydroergotamine", "suffix": " is contraindicated "}, {"to": "7467", "prefix": "", "from": "7451", "name": "Dihydroergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3418", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "dihydroergotamine", "suffix": ": Post-marketing reports indicate that coadministration of c"}, {"to": "7577", "prefix": "that coadministration of clarithromycin with ergotamine or ", "from": "7561", "name": "Dihydroergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3418", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "dihydroergotamine", "suffix": " has been associated with acute ergot toxicity characterized"}, {"to": "7820", "prefix": "mitant administration of clarithromycin with ergotamine or ", "from": "7804", "name": "Dihydroergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3418", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "dihydroergotamine", "suffix": " is contraindicated "}, {"to": "7890", "prefix": "such as ", "from": "7882", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "triazolam", "suffix": " and alprazolam"}, {"to": "8024", "prefix": "rythromycin has been reported to decrease the clearance of ", "from": "8016", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "triazolam", "suffix": " and midazolam, and thus, may increase the pharmacologic eff"}, {"to": "8278", "prefix": " with the concomitant use of clarithromycin and ", "from": "8270", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "triazolam", "suffix": ".Triazolobenziodidiazepines "}, {"to": "7905", "prefix": "such as triazolam and ", "from": "7896", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "alprazolam", "suffix": ""}, {"to": "7934", "prefix": " and related ", "from": "7920", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "benzodiazepines", "suffix": " "}, {"to": "8112", "prefix": ", and thus, may increase the pharmacologic effect of these ", "from": "8098", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "benzodiazepines", "suffix": ". There have been postmarketing reports of drug interactions"}, {"to": "7953", "prefix": "such as ", "from": "7945", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "midazolam", "suffix": ""}, {"to": "8038", "prefix": "s been reported to decrease the clearance of triazolam and ", "from": "8030", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "midazolam", "suffix": ", and thus, may increase the pharmacologic effect of these b"}, {"to": "8480", "prefix": "e.g., ", "from": "8471", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "lovastatin", "suffix": " and simvastatin"}, {"to": "8759", "prefix": "e.g., ", "from": "8750", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "lovastatin", "suffix": " and simvastatin"}, {"to": "8496", "prefix": "e.g., lovastatin and ", "from": "8486", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "simvastatin", "suffix": ""}, {"to": "8775", "prefix": "e.g., lovastatin and ", "from": "8765", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "simvastatin", "suffix": ""}, {"to": "8883", "prefix": "been reported in patients taking these drugs concomitantly.", "from": "8874", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Sildenafil", "suffix": " "}, {"to": "8978", "prefix": " of ", "from": "8969", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "sildenafil", "suffix": ". A similar interaction may occur with clarithromycin; reduc"}, {"to": "9056", "prefix": "ar interaction may occur with clarithromycin; reduction of ", "from": "9047", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "sildenafil", "suffix": " dosage should be considered. "}, {"to": "9124", "prefix": "", "from": "9115", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Sildenafil", "suffix": " "}, {"to": "9219", "prefix": " of ", "from": "9210", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "sildenafil", "suffix": ". A similar interaction may occur with clarithromycin; reduc"}, {"to": "9297", "prefix": "ar interaction may occur with clarithromycin; reduction of ", "from": "9288", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "sildenafil", "suffix": " dosage should be considered. "}, {"to": "8891", "prefix": "", "from": "8886", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C101426", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Viagra", "suffix": ""}, {"to": "9097", "prefix": "See ", "from": "9092", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C101426", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Viagra", "suffix": " package insert."}, {"to": "9132", "prefix": "", "from": "9127", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C101426", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Viagra", "suffix": ""}, {"to": "9338", "prefix": "See ", "from": "9333", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C101426", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "Viagra", "suffix": " package insert."}, {"to": "9487", "prefix": "or clarithromycin with ", "from": "9476", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "cyclosporine", "suffix": ", carbamazepine, tacrolimus, alfentanil, disopyramide, rifab"}, {"to": "9514", "prefix": "or clarithromycin with cyclosporine, carbamazepine, ", "from": "9505", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "tacrolimus", "suffix": ", alfentanil, disopyramide, rifabutin, quinidine, methylpred"}, {"to": "9526", "prefix": "arithromycin with cyclosporine, carbamazepine, tacrolimus, ", "from": "9517", "name": "Alfentanil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015760", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "alfentanil", "suffix": ", disopyramide, rifabutin, quinidine, methylprednisolone, ci"}, {"to": "9551", "prefix": "rine, carbamazepine, tacrolimus, alfentanil, disopyramide, ", "from": "9543", "name": "Rifabutin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/55672", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "rifabutin", "suffix": ", quinidine, methylprednisolone, cilostazol, and bromocripti"}, {"to": "9582", "prefix": "acrolimus, alfentanil, disopyramide, rifabutin, quinidine, ", "from": "9565", "name": "Methylprednisolone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008775", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "methylprednisolone", "suffix": ", cilostazol, and bromocriptine.Concomitant administration o"}, {"to": "9594", "prefix": "l, disopyramide, rifabutin, quinidine, methylprednisolone, ", "from": "9585", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/MESH/C045645", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "cilostazol", "suffix": ", and bromocriptine.Concomitant administration of clarithrom"}, {"to": "9613", "prefix": " rifabutin, quinidine, methylprednisolone, cilostazol, and ", "from": "9601", "name": "Bromocriptine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1760", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "bromocriptine", "suffix": ".Concomitant administration of clarithromycin with cisapride"}, {"to": "9673", "prefix": "criptine.Concomitant administration of clarithromycin with ", "from": "9665", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "cisapride", "suffix": ", pimozide, astemizole, or terfenadine is contraindicated "}, {"to": "9683", "prefix": "ncomitant administration of clarithromycin with cisapride, ", "from": "9676", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "pimozide", "suffix": ", astemizole, or terfenadine is contraindicated "}, {"to": "9695", "prefix": "administration of clarithromycin with cisapride, pimozide, ", "from": "9686", "name": "Astemizole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42328", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "astemizole", "suffix": ", or terfenadine is contraindicated "}, {"to": "9934", "prefix": "th drugs not thought to be metabolized by CYP3A, including ", "from": "9923", "name": "Hexobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5302", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "hexobarbital", "suffix": ", phenytoin, and valproate.\n\n\n"}, {"to": "9945", "prefix": "hought to be metabolized by CYP3A, including hexobarbital, ", "from": "9937", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "phenytoin", "suffix": ", and valproate.\n\n\n"}, {"to": "9960", "prefix": "tabolized by CYP3A, including hexobarbital, phenytoin, and ", "from": "9952", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "38642D80-AAA6-4196-A033-3977FF35B48A", "exact": "valproate", "suffix": ".\n\n\n"}, {"to": "260", "prefix": "ministration\n                     \n                        ", "from": "253", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "Rifampin", "suffix": " is readily absorbed from the gastrointestinal tract. Peak s"}, {"to": "474", "prefix": "dual to individual. Following a single 600 mg oral dose of ", "from": "467", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " in healthy adults, the peak serum concentration averages 7 "}, {"to": "597", "prefix": "mL. Absorption of ", "from": "590", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " is reduced by about 30% when the drug is ingested with food"}, {"to": "691", "prefix": "en the drug is ingested with food.\n                        ", "from": "684", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "Rifampin", "suffix": " is widely distributed throughout the body. It is present in"}, {"to": "848", "prefix": "any organs and body fluids, including cerebrospinal fluid. ", "from": "841", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "Rifampin", "suffix": " is about 80% protein bound. Most of the unbound fraction is"}, {"to": "1051", "prefix": "       In healthy adults, the mean biological half-life of ", "from": "1044", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " in serum averages 3.35  "}, {"to": "1470", "prefix": "uently, no dosage adjustment is required. The half-life of ", "from": "1463", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " at a dose of 720 mg daily has not been established in patie"}, {"to": "1601", "prefix": "with renal failure. Following a single 900 mg oral dose of ", "from": "1594", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " in patients with varying degrees of renal insufficiency, th"}, {"to": "2071", "prefix": "c insufficiency.\n                        After absorption, ", "from": "2064", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " is rapidly eliminated in the bile, and an enterohepatic cir"}, {"to": "2177", "prefix": " an enterohepatic circulation ensues. During this process, ", "from": "2170", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " undergoes progressive deacetylation so that nearly all the "}, {"to": "3003", "prefix": "ne study, pediatric patients 6 to 58 months old were given ", "from": "2996", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " suspended in simple syrup or as dry powder mixed with apple"}, {"to": "3348", "prefix": "2 of ", "from": "3341", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " averaged 2.9 hours. It should be noted that in other studie"}, {"to": "4009", "prefix": "         \n                        \n                        ", "from": "4002", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "Rifampin", "suffix": " inhibits DNA-dependent RNA polymerase activity in susceptib"}, {"to": "4418", "prefix": "           \n                        Organisms resistant to ", "from": "4411", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " are likely to be resistant to other rifamycins.\n           "}, {"to": "4779", "prefix": "can rapidly become predominant. In addition, resistance to ", "from": "4772", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " has been determined to occur as single-step mutations of th"}, {"to": "5230", "prefix": "         \n                        \n                        ", "from": "5223", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "Rifampin", "suffix": " has bactericidal activity in vitro against slow and intermi"}, {"to": "5364", "prefix": " growing M tuberculosis organisms.\n                        ", "from": "5357", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "Rifampin", "suffix": " has been shown to be active against most strains of the fol"}, {"to": "6257", "prefix": " clinical significance is unknown.\n                        ", "from": "6250", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "Rifampin", "suffix": " exhibits in vitro activity against most strains of the foll"}, {"to": "6388", "prefix": "g microorganisms; however, the safety and effectiveness of ", "from": "6381", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " in treating clinical infections due to these microorganisms"}, {"to": "7690", "prefix": "-lactamase production should have no effect on ", "from": "7683", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " activity.\n                     \n                     \n     "}, {"to": "8320", "prefix": " in vitro susceptibility methods are available for testing ", "from": "8313", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " against M tuberculosis organisms. The agar proportion metho"}, {"to": "8461", "prefix": " utilizes Middlebrook 7H10 medium impregnated with ", "from": "8454", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " at a final concentration of 1 mcg"}, {"to": "9013", "prefix": "mL of ", "from": "9006", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": ". Strict adherence to the manufacturer"}, {"to": "9279", "prefix": " different methods can only be compared if the appropriate ", "from": "9272", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " concentration is used for each test method as indicated abo"}, {"to": "10190", "prefix": " or equivalent with ", "from": "10183", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " powder. The MIC values obtained should be interpreted accor"}, {"to": "12145", "prefix": "e technical aspects of the laboratory procedures. Standard ", "from": "12138", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " powder should give the following MIC values:\n              "}, {"to": "12588", "prefix": "with disks to test the susceptibility of microorganisms to ", "from": "12581", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " uses the 5 mcg rifampin disk. Interpretation involves corre"}, {"to": "12612", "prefix": "usceptibility of microorganisms to rifampin uses the 5 mcg ", "from": "12605", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " disk. Interpretation involves correlation of the diameter o"}, {"to": "12722", "prefix": "of the diameter obtained in the disk test with the MIC for ", "from": "12715", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": ".\n                        Reports from the laboratory provid"}, {"to": "12863", "prefix": " the standard single-disk susceptibility test with a 5 mcg ", "from": "12856", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " disk should be interpreted according to the following crite"}, {"to": "13471", "prefix": " technical aspects of the laboratory procedures. The 5 mcg ", "from": "13464", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifampin", "suffix": " disk should provide the following zone diameters in these q"}, {"to": "4465", "prefix": " resistant to rifampin are likely to be resistant to other ", "from": "4456", "name": "Rifamycins", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9385", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "rifamycins", "suffix": ".\n                        \n                           In the"}, {"to": "6832", "prefix": "including ", "from": "6822", "name": "Methicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008712", "setId": "55816042-946d-4bec-9461-bd998628ff45", "exact": "Methicillin", "suffix": "-Resistant S. \n                              aureus"}, {"to": "268", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " is an antiviral agent [see Microbiology "}, {"to": "1001", "prefix": "100 mg twice daily of ", "from": "994", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "1209", "prefix": "seline-corrected QTcS observed at about 12-20 h post-dose. ", "from": "1202", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "1285", "prefix": "100 mg twice daily resulted in a Day 3 mean Cmax of ", "from": "1278", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " approximately 1.4-fold higher than the mean Cmax observed o"}, {"to": "1676", "prefix": "terval prolongations were also noted in subjects receiving ", "from": "1669", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "1949", "prefix": "100 mg twice daily ", "from": "1940", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": ""}, {"to": "2199", "prefix": "100 mg twice daily ", "from": "2192", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "2361", "prefix": " ms was also observed in 40% and 47% of subjects receiving ", "from": "2354", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "2840", "prefix": "          \n                        The pharmacokinetics of ", "from": "2833", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "2967", "prefix": "HIV-1-infected subjects and healthy subjects. Steady-state ", "from": "2958", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " AUC, Cmax, and Cmin in healthy subjects are approximately 5"}, {"to": "3817", "prefix": "             Similar bioavailability was demonstrated when ", "from": "3810", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " 500 mg film-coated tablet "}, {"to": "3869", "prefix": " and ", "from": "3862", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " 200 mg capsule "}, {"to": "4227", "prefix": "                               Absolute bioavailability of ", "from": "4218", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " administered as INVIRASE averaged 4% "}, {"to": "4252", "prefix": "    Absolute bioavailability of saquinavir administered as ", "from": "4245", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " averaged 4% "}, {"to": "4384", "prefix": " of ", "from": "4366", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir mesylate", "suffix": " following a high-fat breakfast "}, {"to": "4640", "prefix": "first-pass metabolism.\n                                    ", "from": "4633", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " in combination with ritonavir at a dose of 1000"}, {"to": "4727", "prefix": "100 mg twice daily provides ", "from": "4718", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " systemic exposures over a 24-hour period that are similar t"}, {"to": "4819", "prefix": "r a 24-hour period that are similar to those achieved with ", "from": "4810", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " soft gel capsules with ritonavir 1000"}, {"to": "4923", "prefix": "100 mg twice daily and greater than that achieved with ", "from": "4914", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " soft gel capsules 1200 mg three times daily "}, {"to": "5749", "prefix": " when ", "from": "5742", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " was given following a high-fat breakfast "}, {"to": "5857", "prefix": ". ", "from": "5848", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " 24-hour AUC and Cmax "}, {"to": "6169", "prefix": "r up to 2 hours.\n                                          ", "from": "6162", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "6864", "prefix": "on following intravenous administration of a 12-mg dose of ", "from": "6855", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " "}, {"to": "6912", "prefix": ", suggesting ", "from": "6903", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " partitions into tissues. Saquinavir was approximately 98% b"}, {"to": "6948", "prefix": ", suggesting saquinavir partitions into tissues. ", "from": "6939", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " was approximately 98% bound to plasma proteins over a conce"}, {"to": "7086", "prefix": "mL. In 2 subjects receiving ", "from": "7068", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir mesylate", "suffix": " 600 mg three times daily, cerebrospinal fluid concentration"}, {"to": "7858", "prefix": "g human liver microsomes have shown that the metabolism of ", "from": "7849", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " is cytochrome P450 mediated with the specific isoenzyme, CY"}, {"to": "8018", "prefix": " 90% of the hepatic metabolism. Based on in vitro studies, ", "from": "8009", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " is rapidly metabolized to a range of mono- and di-hydroxyla"}, {"to": "8162", "prefix": "active compounds. In a mass balance study using 600 mg 14C-", "from": "8144", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir mesylate", "suffix": " "}, {"to": "8358", "prefix": "sing. In an additional 4 subjects administered 10.5 mg 14C-", "from": "8349", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " intravenously, 81% and 3% of the intravenously administered"}, {"to": "8675", "prefix": " after oral administration and the remainder attributed to ", "from": "8666", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " metabolites. Following intravenous administration, 66% of c"}, {"to": "8835", "prefix": "tributed to unchanged drug and the remainder attributed to ", "from": "8826", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " metabolites, suggesting that saquinavir undergoes extensive"}, {"to": "8875", "prefix": "nder attributed to saquinavir metabolites, suggesting that ", "from": "8866", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " undergoes extensive first-pass metabolism.\n                "}, {"to": "8993", "prefix": "                                     Systemic clearance of ", "from": "8984", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " was rapid, 1.14 L"}, {"to": "9108", "prefix": "nous doses of 6, 36, and 72 mg. The mean residence time of ", "from": "9099", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " was 7 hours "}, {"to": "10146", "prefix": "          \n                                                ", "from": "10137", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " pharmacokinetics in patients with renal impairment has not "}, {"to": "10246", "prefix": "ith renal impairment has not been investigated. Only 1% of ", "from": "10237", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " is excreted in the urine, so the impact of renal impairment"}, {"to": "10320", "prefix": "xcreted in the urine, so the impact of renal impairment on ", "from": "10311", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " elimination would likely be minimal. However, subjects with"}, {"to": "10494", "prefix": " have not been studied, and concentrations of ", "from": "10485", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " may be elevated in these populations.\n                     "}, {"to": "11226", "prefix": "hepatic impairment on the steady state pharmacokinetics of ", "from": "11219", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ""}, {"to": "11669", "prefix": " values for ", "from": "11662", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " AUC0-12 and Cmax were 24.3 "}, {"to": "12166", "prefix": "12 and Cmax, which suggests approximately 30% reduction in ", "from": "12157", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " exposure in subjects with moderate hepatic impairment. No d"}, {"to": "12266", "prefix": "te hepatic impairment. No dose adjustment is warranted for ", "from": "12259", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " in HIV-1-infected patients with mild or moderate hepatic im"}, {"to": "13060", "prefix": "ender difference was observed, with females showing higher ", "from": "13051", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " exposure than males "}, {"to": "13182", "prefix": ", in the relative bioavailability study comparing ", "from": "13175", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " 500 mg film-coated tablets to the INVIRASE 200 mg capsules "}, {"to": "13225", "prefix": "study comparing INVIRASE 500 mg film-coated tablets to the ", "from": "13218", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " 200 mg capsules in combination with ritonavir. There was no"}, {"to": "13514", "prefix": "", "from": "13505", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " 1000-mg"}, {"to": "13658", "prefix": "             The effect of race on the pharmacokinetics of ", "from": "13649", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " has not been investigated.\n                                "}, {"to": "13768", "prefix": "                                   The pharmacokinetics of ", "from": "13759", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " have not been evaluated in the elderly.\n                   "}, {"to": "14672", "prefix": "tween 2 and less than 6 years of age received 50 mg per kg ", "from": "14663", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " twice daily "}, {"to": "14961", "prefix": ". For subjects unable to swallow the ", "from": "14954", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " capsules, the contents of INVIRASE 200 mg capsules were mix"}, {"to": "14996", "prefix": "s unable to swallow the INVIRASE capsules, the contents of ", "from": "14989", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " 200 mg capsules were mixed with sugar syrup, or sorbitol sy"}, {"to": "15174", "prefix": ", jam, or baby formula. The mean steady state ", "from": "15165", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " PK parameters for pediatric subjects 2 to less than 6 years"}, {"to": "16749", "prefix": "                                  summarizes the effect of ", "from": "16740", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " soft gel capsules and INVIRASE with and without ritonavir o"}, {"to": "16780", "prefix": " summarizes the effect of saquinavir soft gel capsules and ", "from": "16773", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " with and without ritonavir on the geometric mean AUC and Cm"}, {"to": "17065", "prefix": "coadministered drugs on the geometric mean AUC and Cmax of ", "from": "17056", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": ".\n                                          \n\n\n\n            "}, {"to": "17834", "prefix": "                            \n                              ", "from": "17825", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " is an inhibitor of HIV-1 protease. HIV-1 protease is an enz"}, {"to": "18040", "prefix": "o individual functional proteins found in HIV-1 particles. ", "from": "18031", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " is a peptide-like substrate analogue that binds to the prot"}, {"to": "18168", "prefix": "tease active site and inhibits the activity of the enzyme. ", "from": "18159", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " inhibition prevents cleavage of the viral polyproteins resu"}, {"to": "18708", "prefix": "  \n                              The antiviral activity of ", "from": "18699", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " was assessed in lymphoblastoid and monocytic cell lines and"}, {"to": "18828", "prefix": "lines and in peripheral blood lymphocytes in cell culture. ", "from": "18819", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " inhibited HIV-1 activity in both acutely and chronically in"}, {"to": "19079", "prefix": "vely. In the presence of 40% human serum, the mean EC50 of ", "from": "19070", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " against laboratory strain HIV-1 RF in MT4 cells was 37.7 "}, {"to": "19220", "prefix": "ting a 4-fold increase in the EC50 value. In cell culture, ", "from": "19211", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " demonstrated additive to synergistic effects against HIV-1 "}, {"to": "19437", "prefix": " without enhanced cytotoxicity. ", "from": "19428", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " in combination with the protease inhibitors amprenavir, ata"}, {"to": "19573", "prefix": ", or lopinavir resulted in synergistic antiviral activity. ", "from": "19564", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "Saquinavir", "suffix": " displayed antiviral activity in cell culture against HIV-1 "}, {"to": "19723", "prefix": ". The EC50 and EC90 values of ", "from": "19714", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " against HIV-2 isolates in cell culture ranged from 0.25 nM "}, {"to": "20258", "prefix": "             HIV-1 isolates with reduced susceptibility to ", "from": "20249", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " have been selected during passage in cell culture. Genotypi"}, {"to": "20504", "prefix": "bstitutions were associated with reduced susceptibility to ", "from": "20495", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": ", and conferred an increase in the EC50 value of 8- and 3-fo"}, {"to": "20705", "prefix": " to ", "from": "20696", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " emerged in some subjects treated with INVIRASE. Genotypic a"}, {"to": "20752", "prefix": " to saquinavir emerged in some subjects treated with ", "from": "20745", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": ". Genotypic analysis of these isolates identified resistance"}, {"to": "21020", "prefix": "I, V82A and I84V that contributed additional resistance to ", "from": "21011", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": ". Forty-one isolates from 37 subjects failing therapy with I"}, {"to": "21087", "prefix": ". Forty-one isolates from 37 subjects failing therapy with ", "from": "21080", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " had a median decrease in susceptibility to saquinavir of 4."}, {"to": "21141", "prefix": "y with INVIRASE had a median decrease in susceptibility to ", "from": "21132", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " of 4.3-fold.\n                              The degree of re"}, {"to": "21253", "prefix": " The degree of reduction in cell culture susceptibility to ", "from": "21244", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " of clinical isolates bearing substitutions G48V and L90M de"}, {"to": "21651", "prefix": "ddress the development of resistance in patients receiving ", "from": "21642", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": ""}, {"to": "22230", "prefix": " to ", "from": "22221", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " following therapy with INVIRASE were evaluated for cross-re"}, {"to": "22262", "prefix": " to saquinavir following therapy with ", "from": "22255", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "INVIRASE", "suffix": " were evaluated for cross-resistance to amprenavir, indinavi"}, {"to": "22965", "prefix": "ter treatment failure with amprenavir, cross-resistance to ", "from": "22956", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": " was evaluated.  HIV-1 isolates from 22"}, {"to": "23163", "prefix": "I, I50V, I54L, V32I, I47V, and I84V were susceptible to ", "from": "23154", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "saquinavir", "suffix": ".\n                           \n                           \n  "}, {"to": "666", "prefix": "", "from": "655", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "moxifloxacin", "suffix": " 400 mg once daily"}, {"to": "2490", "prefix": " of subjects in the active control ", "from": "2479", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "moxifloxacin", "suffix": " arm and 5% in the placebo arm experienced PR prolongation o"}, {"to": "1011", "prefix": "", "from": "1003", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": ", respectively. There is a delayed effect between QTc interv"}, {"to": "1219", "prefix": "", "from": "1211", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " 1500"}, {"to": "1686", "prefix": "", "from": "1678", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " in the same study on Day 3. The maximum mean "}, {"to": "1959", "prefix": "", "from": "1951", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " respectively. The maximum mean "}, {"to": "2209", "prefix": "", "from": "2201", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " respectively. In this study using healthy subjects, PR inte"}, {"to": "2371", "prefix": "", "from": "2363", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " 1000"}, {"to": "2850", "prefix": "", "from": "2842", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " 1000"}, {"to": "3939", "prefix": " were administered with low-dose ", "from": "3931", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " "}, {"to": "4670", "prefix": "                              INVIRASE in combination with ", "from": "4662", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " at a dose of 1000"}, {"to": "4852", "prefix": "r to those achieved with saquinavir soft gel capsules with ", "from": "4844", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " 1000"}, {"to": "6179", "prefix": "", "from": "6171", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " should be taken within 2 hours after a meal.\n              "}, {"to": "11236", "prefix": "", "from": "11228", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " "}, {"to": "13271", "prefix": "ablets to the INVIRASE 200 mg capsules in combination with ", "from": "13263", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": ". There was no evidence that age and body weight explained t"}, {"to": "13532", "prefix": "", "from": "13524", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " 100-mg twice daily"}, {"to": "14743", "prefix": " boosted with ", "from": "14735", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " at 3 mg"}, {"to": "16807", "prefix": "saquinavir soft gel capsules and INVIRASE with and without ", "from": "16799", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": " on the geometric mean AUC and Cmax of coadministered drugs."}, {"to": "21661", "prefix": "", "from": "21653", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": ".\n                           \n                           \n  "}, {"to": "22349", "prefix": " cross-resistance to amprenavir, indinavir, nelfinavir and ", "from": "22341", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": ". Six of the 22 isolates "}, {"to": "22848", "prefix": "with available data remained susceptible to nelfinavir and ", "from": "22840", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "ritonavir", "suffix": ", respectively.\n                              After treatmen"}, {"to": "15053", "prefix": "f INVIRASE 200 mg capsules were mixed with sugar syrup, or ", "from": "15046", "name": "Sorbitol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9945", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "sorbitol", "suffix": " syrup "}, {"to": "19344", "prefix": "", "from": "19335", "name": "Didanosine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3364", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "didanosine", "suffix": ", lamivudine, nevirapine, stavudine and zidovudine"}, {"to": "19356", "prefix": "didanosine, ", "from": "19347", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D019259", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "lamivudine", "suffix": ", nevirapine, stavudine and zidovudine"}, {"to": "19368", "prefix": "didanosine, lamivudine, ", "from": "19359", "name": "Nevirapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D019829", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "nevirapine", "suffix": ", stavudine and zidovudine"}, {"to": "19379", "prefix": "didanosine, lamivudine, nevirapine, ", "from": "19371", "name": "Stavudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/59763", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "stavudine", "suffix": " and zidovudine"}, {"to": "19394", "prefix": "didanosine, lamivudine, nevirapine, stavudine and ", "from": "19385", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "zidovudine", "suffix": ""}, {"to": "19492", "prefix": "ty. Saquinavir in combination with the protease inhibitors ", "from": "19483", "name": "amprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C095108", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "amprenavir", "suffix": ", atazanavir, or lopinavir resulted in synergistic antiviral"}, {"to": "22312", "prefix": "erapy with INVIRASE were evaluated for cross-resistance to ", "from": "22303", "name": "amprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C095108", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "amprenavir", "suffix": ", indinavir, nelfinavir and ritonavir. Six of the 22 isolate"}, {"to": "22712", "prefix": " to ", "from": "22703", "name": "amprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C095108", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "amprenavir", "suffix": " and indinavir, respectively. Four of 16 "}, {"to": "22933", "prefix": "                              After treatment failure with ", "from": "22924", "name": "amprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C095108", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "amprenavir", "suffix": ", cross-resistance to saquinavir was evaluated.  HIV-1 isola"}, {"to": "23050", "prefix": "22 subjects failing treatment with ", "from": "23041", "name": "amprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C095108", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "amprenavir", "suffix": " and containing one or more substitutions M46L"}, {"to": "19504", "prefix": "ir in combination with the protease inhibitors amprenavir, ", "from": "19495", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "atazanavir", "suffix": ", or lopinavir resulted in synergistic antiviral activity. S"}, {"to": "19518", "prefix": "on with the protease inhibitors amprenavir, atazanavir, or ", "from": "19510", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "lopinavir", "suffix": " resulted in synergistic antiviral activity. Saquinavir disp"}, {"to": "22323", "prefix": "NVIRASE were evaluated for cross-resistance to amprenavir, ", "from": "22315", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "indinavir", "suffix": ", nelfinavir and ritonavir. Six of the 22 isolates "}, {"to": "22726", "prefix": " to amprenavir and ", "from": "22718", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "indinavir", "suffix": ", respectively. Four of 16 "}, {"to": "22335", "prefix": "e evaluated for cross-resistance to amprenavir, indinavir, ", "from": "22326", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "nelfinavir", "suffix": " and ritonavir. Six of the 22 isolates "}, {"to": "22834", "prefix": " with available data remained susceptible to ", "from": "22825", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "c00d1607-ac36-457b-a34b-75ad74f9cf0a", "exact": "nelfinavir", "suffix": " and ritonavir, respectively.\n                              "}]